A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Protocol No
EPIZYME-SET-101
Phase
I
Summary

This project is being done to understand more about whether EZM0414 will be a safe and effective treatment in the future for patients with different types of cancers.

Description
Study of EZM0414 in R/R MM and R/R DLBCL
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL